baclofen "paranova" 10 mg tabletter
paranova danmark a/s - baclofen - tabletter - 10 mg
gestoden/ethinylestradiol "2care4" 75+20 mikrogram overtrukne tabletter
2care4 aps - ethinylestradiol, gestoden - overtrukne tabletter - 75+20 mikrogram
baclofen "paranova" 25 mg tabletter
paranova danmark a/s - baclofen - tabletter - 25 mg
isturisa
recordati rare diseases - osilodrostat fosfat - cushing syndrome - kortikosteroider til systemisk brug - isturisa er indiceret til behandling af endogene cushings syndrom hos voksne.
furosemid "hameln" 10 mg/ml injektionsvæske, opløsning
hameln pharma gmbh - furosemid - injektionsvæske, opløsning - 10 mg/ml
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinale stromale tumorer - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressants, selektiv immunosuppressive - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
teriflunomide "sandoz" 14 mg filmovertrukne tabletter
sandoz a/s - teriflunomid - filmovertrukne tabletter - 14 mg